GlobeNewswire by notified

Fingerprint Cards AB (publ) avser emittera nya aktier som betalning i samband med den tredje amorteringen och räntebetalningen under dess utestående konvertibler


Den 19 september 2023 offentliggjorde Fingerprint Cards AB (publ) (“Fingerprints” eller “Bolaget”) att de beslutat om en emission av konvertibler med ett nominellt belopp om 160 MSEK (”Konvertiblerna”) till en entitet som förvaltas av Heights Capital Management, Inc. (”HCM”). I enlighet med villkoren för Konvertiblerna (”Villkoren”) ska Konvertiblerna amorteras i lika stora delbetalningar (”Avbetalningarna”) att betalas varannan månad tillsammans med upplupen ränta (vardera, en ”Avbetalningsdag”). De återstående schemalagda amorterings- och avbetalningsdagarna under Konvertiblerna anges nedan.

Den tredje Avbetalningsdagen är den 19 mars 2024 och amorterings- och räntebeloppet är 7 304 908 SEK (”Amorterings- och räntebeloppet”). Som tidigare offentliggjorts kan Bolaget i enlighet med Villkoren betala Avbetalningarna kontant eller i B-aktier.

Bolaget kommer nu att betala Amorterings- och räntebeloppet i nya B-aktier (”Aktiebetalningen”). Priset för de nya aktierna (”Avbetalningspriset”) tillsammans med antalet aktier i Aktiebetalningen kommer att beräknas i enlighet med Villkoren och kommer att offentliggöras av Bolaget i ett separat pressmeddelande omedelbart efter det att beräkningsagenten tillhandahållit Bolaget informationen i enlighet med Villkoren. Pressmeddelandet förväntas publiceras den 20 mars 2024. Bolaget uppskattar att, förutsatt ett Avbetalningspris om 0,88 SEK (90 procent av B-aktiens stängningskurs per igår), utspädningseffekten av nyemissionen inte kommer att överstiga 1,4 procent.

Betalningsplanen för framtida Avbetalningar och räntebetalningar på Konvertiblerna återfinns nedan och Bolaget kan vid varje framtida amortering- och räntebetalningsdag välja att betala relevant Avbetalning och/eller räntebetalning genom betalning i aktier. Priset per aktie, antalet aktier och utspädningseffekten kommer i sådana fall att offentliggöras genom separata pressmeddelanden.

Schemalagda amortering- och räntebetalningsdagar enligt Villkoren
19 mars 202419 januari 202519 januari 202619 januari 2027
19 maj 202419 mars 202519 mars 2026
19 juli 202419 maj 202519 maj 2026
19 september 202419 juli 202519 juli 2026
19 november 202419 september 202519 september 2026
19 november 202519 november 2026

För information, vänligen kontakta:
Adam Philpott, VD

Per Sundqvist, CFO

Investor Relations:
+46(0)10-172 00 10

+46(0)10-172 00 20

Informationen lämnades , genom ovanstående kontaktpersons försorg, för offentliggörande den 15 mars 2024 kl. 17:45 CET.

Om Fingerprints
Fingerprints är världens ledande biometriföretag. Vi tror på ett säkert och användarvänligt universum, där du är nyckeln till allt. Våra lösningar finns i miljontals elektroniska produkter och applikationer och används flera miljarder gånger varje dag. Vi erbjuder säker och bekväm identifiering och autentisering – with a human touch. För mer information besök vår webbplats, läs vår blogg och följ oss på Twitter. Fingerprints är noterat på Nasdaq Stockholm (FING B).


För att se det här innehållet från måste du ge ditt medgivande sidans topp.
För att se det här innehållet från måste du ge ditt medgivande sidans topp.


GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Följ GlobeNewswire by notified

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire by notified

Convening Notice for Annual General Meeting and Extraordinary General Meeting of Shareholders17.4.2024 02:00:00 CEST | Press release

Convening Notice for Annual General Meeting and Extraordinary General Meeting of Shareholders MILLICOM INTERNATIONAL CELLULAR S.A. Registered Address: 2, Rue du Fort Bourbon L-1249 Luxembourg, Grand Duchy of Luxembourg – R.C.S. Luxembourg: B 40.630 – I. NOTICE The annual general meeting (“AGM”) and subsequent extraordinary general meeting (“EGM”) of the shareholders of MILLICOM INTERNATIONAL CELLULAR S.A. (“Millicom” or the “Company”) is hereby convened to be held at Hotel Le Royal, 12 Bd Royal, 2449 Luxembourg on Thursday, May 23, 2024, at 11:00 a.m. Central European Time ("CET"). To attend the AGM and EGM or vote by proxy, please follow the instructions in section IV: “Right to participate at the AGM and the EGM”. The AGM and EGM will consider and vote on the agenda points listed below. Please refer to section IX: “Notes to the Agenda Points of the AGM and EGM” to find detailed information about these proposals. II. AGENDA AGM To elect the chair of the AGM and to empower the chair of

Millicom’s Nomination Committee’s proposal for Board of Directors17.4.2024 02:00:00 CEST | Press release

Millicom’s Nomination Committee’s proposal for Board of Directors Luxembourg, April 17, 2024 – In advance of the Annual General Meeting of shareholders (“AGM”) of Millicom International Cellular S.A. (“Millicom”), to be held on May 23, 2024, Millicom’s Nomination Committee proposes: The election of Maxime Lombardini and Justine Dimovic as new Directors of the Board; The re-election of María Teresa Arnal Machado, Bruce Churchill, Aude Durand, Tomas Eliasson, Mauricio Ramos, Thomas Reynaud, and Blanca Treviño de Vega as Directors of the Board; and the election of Mauricio Ramos as Chair of the Board. Pernille Erenbjerg and Michael Golan have decided not to seek re-election. Maxime Lombardini will bring his extensive experience and track record in leading businesses in the telecommunications industry, as well as the strong knowledge of Millicom that he has gained while serving as President and Chief Operating Officer since September 2023. Justine Dimovic will bring a wealth of capital all

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)16.4.2024 23:30:00 CEST | Press release

SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the U.S. on or after February 21, 2025, following a settlement agreement with Johnson & Johnson, the manufacturer of StelaraSELARSDI was developed and is manufactured by Alvotech using murine cell (Sp2/0) and a continuous perfusion process, which are the same type of cells and process used for the production of Stelara REYKJAVIK, ICELAND & PARSIPPANY, NJ — Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. Unde

Atico Reports Consolidated Financial Results for 202316.4.2024 22:30:29 CEST | Press release

(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTC: ATCMF) today announced its financial results for the year ended December 31, 2023, posting income from mining operations of $7.4 million and a net loss of $5.8 million. Production for the year at Atico’s El Roble mine totaled 13.2 million pounds (“lbs”) of copper and 10,149 ounces (“oz”) of gold in concentrate at a cash cost(1) of $2.04 per payable pound of copper(2). Fernando E. Ganoza, CEO and Director, commented, "we had a challenging year overall, with the first half of the year facing lower than expected head grades and lower throughput due to mechanical and operational issues, coupled with a significant appreciation in the Colombian Peso throughout the year which materially increased our costs. Despite these challenges the team did a great job getting El Roble mine back on track in the

Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program16.4.2024 22:10:00 CEST | Press release

Due to the broad diversity in the UV1 Phase II program and the encouraging results from previous UV1 trials, Ultimovacs remain confident in UV1’s potential and are strongly committed to bringing the company across the next important data points: The readout from FOCUS in Q3 2024 and DOVACC results in H1 2025Activity level adjustments and operational prioritization are implemented to sustain the financial runway, including a workforce reduction of approximately 40% The operational adjustment plan extends the anticipated cash runway to the fourth quarter of 2025, through the readout from the Phase II DOVACC trial Oslo, April 16, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces a plan to optimize its business operations to support the continuous advancement of UV1 and long-term business growth. “We remain dedicated to our investigation of the potential impact of UV1 vaccine across several c

HiddenA line styled icon from Orion Icon Library.Eye